Why do anti-inflammatory therapies fail to improve insulin sensitivity?

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 182-188

  Gao, Zhan Guo ^a   Ye, Jian Ping ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Inflammation; insulin resistance; insulin sensitizer; obesity; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACYL COENZYME A; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; DIACYLGLYCEROL; FATTY ACID; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; MURAGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BLADDER CANCER; CARDIOTOXICITY; DRUG INDUCED CANCER; DRUG TREATMENT FAILURE; ENERGY EXPENDITURE; ENERGY METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER NECROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; OBESITY;

EID: 84856912681     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.131     Document Type: Review

References (109)

1. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91. (Pubitemid 23036092)
2. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic infammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30. (Pubitemid 38063705)
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808. (Pubitemid 38063703)
4. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic infammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293: E1118-28. (Pubitemid 47535846)
5. Larsen OA, Lassen NA, Quaade F. Blood fow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 1966; 66: 337-45.
6. Crandall DL, Goldstein BM, Huggins F, Cervoni P. Adipocyte blood fow: infuence of age, anatomic location, and dietary manipulation. Am J Physiol 1984; 247: R46-51. (Pubitemid 14090880)
7. West DB, Prinz WA, Francendese AA, Greenwood MR. Adipocyte blood fow is decreased in obese Zucker rats. Am J Physiol 1987; 253: R228-33.
8. Brose N, Rosenmund C. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. J Cell Sci 2002; 115: 4399-411. (Pubitemid 36004402)
9. Costanzi S, Neumann S, Gershengorn MC. Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem 2008; 283: 16269-73.
10. Aldhahi W, Hamdy O. Adipokines, infammation, and the endothelium in diabetes. Curr Diab Rep 2003; 3: 293-8.
11. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278: 37041-51. (Pubitemid 37175218)
12. Weigert C, Brodbeck K, Staiger H, Kausch C, Machicao F, Häring HU, et al. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 2004; 279: 23942-52. (Pubitemid 38725252)
13. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 2004; 18: 2024-34. (Pubitemid 39006506)
14. Nakamura T, Furuhashi M, Li P, Cao H, Tuncman G, Sonenberg N, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010; 140: 338-48.
15. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61. (Pubitemid 39372439)
16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
17. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-8. (Pubitemid 26052915)
18. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-5. (Pubitemid 29278870)
19. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingo-myelinase. J Biol Chem 1996; 271: 13018-22.
20. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-54. (Pubitemid 30180265)
21. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steato-hepatitis. Semin Liver Dis 2001; 21: 27-41.
22. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002; 277: 48115-21. (Pubitemid 35470759)
23. De Fea K, Roth RA, Modulation of insulin receptor substrate-1 tyro-sine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 1997; 272: 31400-6. (Pubitemid 28013276)
24. Engelman JA, Berg AH, Lewis RY, Lisanti MP, Scherer PE. Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. Mol Endocrinol 2000; 14: 1557-69.
25. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2001; 107: 181-9. (Pubitemid 32096834)
26. De Fea K, Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry, 1997; 36: 12939-47. (Pubitemid 27465406)
27. Li Y, Soos TJ, Li X, Wu J, Degennaro M, Sun X, et al. Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). J Biol Chem 2004; 279: 45304-7. (Pubitemid 39491511)
28. Ravichandran LV, Esposito DL, Chen J, Quon MJ. Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J Biol Chem 2001; 276: 3543-9.
29. Paz K, Liu YF, Shorer H, Hemi R, LeRoith D, Quan M, et al. Phos-phorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 1999; 274: 28816-22.
30. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci U S A 1997; 94: 9660-4.
31. Ilouz R, Kowalsman N, Eisenstein M, Eldar-Finkelman H. Identifca-tion of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. J Biol Chem 2006; 281: 30621-30. (Pubitemid 44582118)
32. Liberman Z, Eldar-Finkelman H. Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J Biol Chem 2005; 280: 4422-8. (Pubitemid 40288606)
33. Kim JA, Yeh DC, Ver M, Li Y, Carranza A, Conrads TP, et al. Phos-phorylation of Ser24 in the pleckstrin homology domain of insulin receptor substrate-1 by Mouse Pelle-like kinase/interleukin-1 receptor-associated kinase: cross-talk between infammatory signaling and insulin signaling that may contribute to insulin resistance. J Biol Chem 2005; 280: 23173-83. (Pubitemid 40853229)
34. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A 2001; 98: 4640-5. (Pubitemid 32295029)
35. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000; 14: 783-94. (Pubitemid 32260492)
36. Zhang J, Gao Z, Yin J, Quon MJ, Ye J. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem 2008; 283: 35375-82.
37. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-8. (Pubitemid 40321355)
38. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63. (Pubitemid 30365393)
39. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006; 103: 18154-9. (Pubitemid 44871628)
40. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006: re13.
41. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-79.
42. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J 1991; 10: 3805-17. (Pubitemid 21905409)
43. Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N, et al. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest 1998; 102: 1645-52. (Pubitemid 28516249)
44. Gao Z, He Q, Peng B, Chiao PJ, Ye J. Regulation of nuclear translocation of HDAC3 by IkappaBalpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function. J Biol Chem 2006; 281: 4540-7. (Pubitemid 43847886)
45. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 1998; 3: d169-75.
46. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-47. (Pubitemid 14229053)
47. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-4. (Pubitemid 29241025)
48. Schmitz-Peiffer C, Oakes ND, Browne CL, Kraegen EW, Biden TJ. Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653. Am J Physiol 1997; 273: E915-21.
49. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007; 10: 142-8. (Pubitemid 46220305)
50. Thompson AL, Cooney GJ. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 2000; 49: 1761-5.
51. Utaka S, Avesani CM, Draibe SA, Kamimura MA, Andreoni S, Cuppari L. Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. Am J Clin Nutr 2005; 82: 801-5. (Pubitemid 43779693)
52. Moldawer LL, Georgieff M, Lundholm K. Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 1987; 7: 263-74. (Pubitemid 17149440)
53. Barot LR, Rombeau JL, Steinberg JJ, Crosby LO, Feurer ID, Mullen JL. Energy expenditure in patients with infammatory bowel disease. Arch Surg 1981; 116: 460-2. (Pubitemid 11152316)
54. Chan AT, Fleming CR, O'Fallon WM, Huizenga KA. Estimated versus measured basal energy requirements in patients with Crohn's disease. Gastroenterology 1986; 91: 75-8. (Pubitemid 16086657)
55. Strasser F. Appraisal of current and experimental approaches to the treatment of cachexia. Curr Opin Support Palliat Care 2007; 1: 312-6.
56. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89: 1763-73. (Pubitemid 27516230)
57. Tang T, Zhang J, Yin J, Staszkiewicz J, Gawronska-Kozak B, Jung DY, et al. Uncoupling of infammation and insulin resistance by NF-kappaB in transgenic mice through elevated energy expenditure. J Biol Chem 2010; 285: 4637-44.
58. Gao Z, Yin J, Zhang J, He Q, McGuinness OP, Ye J. Inactivation of NF-kappaB p50 leads to insulin sensitization in liver through post-trans-lational inhibition of p70S6K. J Biol Chem 2009; 284: 18368-76.
59. Pamir N, McMillen TS, Kaiyala KJ, Schwartz MW, LeBoeuf RC. Receptors for tumor necrosis factor-alpha play a protective role against obesity and alter adipose tissue macrophage status. Endocrinology 2009; 150: 4124-34.
60. Chida D, Osaka T, Hashimoto O, Iwakura Y. Combined interleukin-6 and interleukin-1 defciency causes obesity in young mice. Diabetes 2006; 55: 971-7. (Pubitemid 44100171)
61. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-defcient mice develop mature-onset obesity. Nat Med 2002; 8: 75-9. (Pubitemid 34101732)
62. Ye J, Keller JN. Regulation of energy metabolism by infammation: a feedback response in obesity and calorie restriction. Aging (Albany NY) 2010; 2: 361-8.
63. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-9.
64. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156: 3961-9. (Pubitemid 26137683)
65. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801. (Pubitemid 44033299)
66. Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1901; 1: 760-2.
67. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80. (Pubitemid 28520452)
68. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 2003; 278: 24944-50. (Pubitemid 37548655)
69. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63. (Pubitemid 36091626)
70. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fsh oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002; 48: 877-83. (Pubitemid 34587587)
71. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305: 2556-64.
72. Burén J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol 2002; 146: 419-29. (Pubitemid 34257654)
73. Perry CG, Spiers A, Cleland SJ, Lowe GD, Petrie JR, Connell JM. Glucocorticoids and insulin sensitivity: dissociation of insulin's metabolic and vascular actions. J Clin Endocrinol Metab 2003; 88: 6008-14. (Pubitemid 38033086)
74. Böni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses JA, Kerr-Conte J, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008; 93: 4065-74.
75. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147. (Pubitemid 26086851)
76. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60.
77. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M,, et al. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997; 46: 1526-31. (Pubitemid 27369096)
78. Schreyer SA, Chua Jr SC, LeBoeuf RC. Obesity and diabetes in TNF-alpha receptor-defcient mice. J Clin Invest 1998; 102: 402-11. (Pubitemid 28335200)
79. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-25. (Pubitemid 41527607)
80. Lo J, Bernstein LE, Canavan B, Torriani M, Jackson MB, Ahima RS, et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 2007; 293: E102-9. (Pubitemid 47105923)
81. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-5. (Pubitemid 26225502)
82. Paquot N, Castillo MJ, Lefèbvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-9. (Pubitemid 32269392)
83. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007; 36: 91-6. (Pubitemid 46685768)
84. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, et al. Interleukin-6-defcient mice develop hepatic infammation and systemic insulin resistance. Diabetologia 2010; 53: 2431-41.
85. Franckhauser S, Elias I, Rotter Sopasakis V, Ferré T, Nagaev I, Andersson CX, et al. Overexpression of Il6 leads to hyper-insulinaemia, liver infammation and reduced body weight in mice. Diabetologia 2008; 51: 1306-16.
86. Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF. Human IL6 enhances leptin action in mice. Diabetologia 2010; 53: 525-35.
87. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 2009; 58: 2525-35.
88. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009; 58: 2574-82.
89. Kowalski GM, Nicholls HT, Risis S, Watson NK, Kanellakis P, Bruce CR, et al. Defciency of haematopoietic-cell-derived IL-10 does not exacerbate high-fat-diet-induced infammation or insulin resistance in mice. Diabetologia 2011; 54: 888-99.
90. den Boer MA, Voshol PJ, Schröder-van der Elst JP, Korsheninnikova E, Ouwens DM, Kuipers F, et al. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 2006; 147: 4553-8. (Pubitemid 44402159)
91. Kohl A, Gögebakan O, Möhlig M, Osterhoff M, Isken F, Pfeiffer AF, et al. Increased interleukin-10 but unchanged insulin sensitivity after 4 weeks of (1,3)(1,6)-beta-glycan consumption in overweight humans. Nutr Res 2009; 29: 248-54.
92. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77: 289-312.
93. Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-9.
94. Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev 2000; 14: 45-54. (Pubitemid 30051578)
95. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-35. (Pubitemid 39050375)
96. Gilbert RE, Huang Q, Thai K, Advani SL, Lee K, Yuen DA, et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int 2011; 79: 1312-21.
97. Christensen DP, Dahllöf M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 2011; 17: 378-390.
98. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509-17.
99. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 2002; 3: 903-10. (Pubitemid 35460789)
100. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 2005; 19: 453-61. (Pubitemid 40256277)
101. Miard S, Fajas L. Atypical transcriptional regulators and cofactors of PPARgamma. Int J Obes (Lond) 2005; 29: S10-2. (Pubitemid 40343164)
102. Zhang J, Henagan TM, Gao Z, Ye J. Inhibition of glyceroneogenesis by histone deacetylase 3 contributes to lipodystrophy in mice with adipose tissue infammation. Endocrinology 2011; 152: 1829-38.
103. Rahman I. Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochem Pharmacol 2002; 64: 935-42. (Pubitemid 35232267)
104. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in infammatory lung diseases. COPD 2005; 2: 445-55. (Pubitemid 43879443)
105. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of infammatory diseases? Drug Discov Today 2005; 10: 197-204. (Pubitemid 40222231)
106. Dinarello CA. Inhibitors of histone deacetylases as anti-infammatory drugs. Ernst Schering Res Found Workshop 2006; 56: 45-60.
107. Zhang L, Fang H, Xu W. Strategies in developing promising histone deacetylase inhibitors. Med Res Rev 2010; 30: 585-602.
108. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of infammation and immunity. Trends Immunol 2011; 32: 335-43.
109. McGee SL, Hargreaves M. Histone modifications and exercise adaptations. J Appl Physiol 2011; 110: 258-63.